About GW Pharmaceuticals PLC (NASDAQ:GWPH)
GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company's lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD). The Company offers Sativex (nabiximols), which is indicated for the treatment of spasticity due to multiple sclerosis (MS). The Company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. The Commercial segment distributes and sells the Company's commercial products. The Sativex Research and Development segment seeks to maximize the potential of Sativex through the development of new indications. The Pipeline Research and Development segment seeks to develop cannabinoid medications other than Sativex across a range of therapeutic areas using its cannabinoid technology platform.
Industry, Sector and Symbol
Industry Bio Therapeutic Drugs
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Annual Sales$13.32 million
Price / Sales243.60
Price / CashN/A
Book Value$22.55 per share
Price / Book5.68
Return on Equity-28.80%
Return on Assets-25.20%
Frequently Asked Questions for GW Pharmaceuticals PLC (NASDAQ:GWPH)
What is GW Pharmaceuticals PLC's stock symbol?
GW Pharmaceuticals PLC trades on the NASDAQ under the ticker symbol "GWPH."
How were GW Pharmaceuticals PLC's earnings last quarter?
GW Pharmaceuticals PLC (NASDAQ:GWPH) released its earnings results on Wednesday, February, 10th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($1.53) by $1.43. The biopharmaceutical company had revenue of $5.40 million for the quarter, compared to the consensus estimate of $4.61 million. GW Pharmaceuticals PLC had a negative return on equity of 28.80% and a negative net margin of 1,384.41%. The business's quarterly revenue was down 54.0% compared to the same quarter last year. During the same quarter last year, the business posted ($0.01) earnings per share. View GW Pharmaceuticals PLC's Earnings History.
When will GW Pharmaceuticals PLC make its next earnings announcement?
Where is GW Pharmaceuticals PLC's stock going? Where will GW Pharmaceuticals PLC's stock price be in 2017?
8 equities research analysts have issued twelve-month price targets for GW Pharmaceuticals PLC's stock. Their predictions range from $61.00 to $208.00. On average, they anticipate GW Pharmaceuticals PLC's share price to reach $146.25 in the next twelve months. View Analyst Ratings for GW Pharmaceuticals PLC.
What are Wall Street analysts saying about GW Pharmaceuticals PLC stock?
Here are some recent quotes from research analysts about GW Pharmaceuticals PLC stock:
- 1. Cantor Fitzgerald analysts commented, "Tonight (11/20), the American Epilepsy Society (AES) published the abstracts for the upcoming annual meeting in early December." (11/20/2017)
- 2. According to Zacks Investment Research, "GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company's lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and neuropathic pain. It operates primarily in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc is based in Salisbury, the United Kingdom. " (7/24/2017)
- 3. Maxim Group analysts commented, "GW pharmaceuticals announced publication of data from the P3 study of Epidiolex (oral CBD, cannabidiol) in pediatric Dravet Syndrome in The New England Journal of Medicine (NEJM)." (5/25/2017)
Who are some of GW Pharmaceuticals PLC's key competitors?
Some companies that are related to GW Pharmaceuticals PLC include Neurocrine Biosciences (NBIX), Bioverativ (BIVV), Shire-Nps Pharmaceuticals (NPSP), TESARO (TSRO), BeiGene (BGNE), Sarepta Therapeutics (SRPT), Auspex Pharmaceuticals (ASPX), AveXis (AVXS), Clovis Oncology (CLVS), Agios Pharmaceuticals (AGIO), Spark Therapeutics (ONCE), Halozyme Therapeutics (HALO), China Biologic Products (CBPO), Insmed (INSM), Loxo Oncology (LOXO), Aerie Pharmaceuticals (AERI), Array BioPharma (ARRY) and Ultragenyx Pharmaceutical (RARE).
Who are GW Pharmaceuticals PLC's key executives?
GW Pharmaceuticals PLC's management team includes the folowing people:
- Geoffrey W. Guy, Executive Chairman of the Board (Age 60)
- Justin Gover, Chief Executive Officer, Director (Age 43)
- Adam David George, Chief Financial Officer, Company Secretary, Director (Age 44)
- Christopher John Tovey, Chief Operating Officer, Executive Director (Age 49)
- Julian S. Gangolli, Executive Director (Age 59)
- James Julian Noble, Non-Executive Deputy Chairman of the Board, Senior Independent Director (Age 55)
- Cabot Brown, Non-Executive Independent Director (Age 53)
- Thomas Gerard Lynch, Non-Executive Independent Director (Age 58)
Who owns GW Pharmaceuticals PLC stock?
GW Pharmaceuticals PLC's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Janus Henderson Group PLC (2.83%), Jennison Associates LLC (1.95%), Pictet Asset Management Ltd. (1.40%), Victory Capital Management Inc. (0.97%), Point72 Asset Management L.P. (0.63%) and Van ECK Associates Corp (0.15%). View Institutional Ownership Trends for GW Pharmaceuticals PLC.
Who sold GW Pharmaceuticals PLC stock? Who is selling GW Pharmaceuticals PLC stock?
GW Pharmaceuticals PLC's stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Advisors Asset Management Inc., Sivik Global Healthcare LLC, ING Groep NV, Stifel Financial Corp, Investment Centers of America Inc. and FNY Partners Fund LP. View Insider Buying and Selling for GW Pharmaceuticals PLC.
Who bought GW Pharmaceuticals PLC stock? Who is buying GW Pharmaceuticals PLC stock?
GW Pharmaceuticals PLC's stock was acquired by a variety of institutional investors in the last quarter, including Pictet Asset Management Ltd., Perceptive Advisors LLC, Point72 Asset Management L.P., Ameriprise Financial Inc., Janus Henderson Group PLC, Van ECK Associates Corp, JPMorgan Chase & Co. and Janney Montgomery Scott LLC. View Insider Buying and Selling for GW Pharmaceuticals PLC.
How do I buy GW Pharmaceuticals PLC stock?
Shares of GW Pharmaceuticals PLC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is GW Pharmaceuticals PLC's stock price today?
One share of GW Pharmaceuticals PLC stock can currently be purchased for approximately $128.15.
How big of a company is GW Pharmaceuticals PLC?
GW Pharmaceuticals PLC has a market capitalization of $3.20 billion and generates $13.32 million in revenue each year. The biopharmaceutical company earns $-90,670,000.00 in net income (profit) each year or ($5.43) on an earnings per share basis. GW Pharmaceuticals PLC employs 496 workers across the globe.
How can I contact GW Pharmaceuticals PLC?
GW Pharmaceuticals PLC's mailing address is SOVEREIGN HOUSE VISION PARK HISTON, CAMBRIDGE X0, CB24 9BZ. The biopharmaceutical company can be reached via phone at 44-12-2326-6800 or via email at [email protected]
MarketBeat Community Rating for GW Pharmaceuticals PLC (GWPH)MarketBeat's community ratings are surveys of what our community members think about GW Pharmaceuticals PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History and Estimates Chart for GW Pharmaceuticals PLC (NASDAQ:GWPH)
Earnings History by Quarter for GW Pharmaceuticals PLC (NASDAQ GWPH)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|12/4/2017|| || || || || || || || |
|8/7/2017||6/30/2017||($1.73)||($2.07)||$2.10 million||$3.14 million||View||Listen|
|5/9/2017||3/31/2017||($1.50)||($1.70)||$2.07 million||$2.04 million||View||Listen|
|2/7/2017||Q117||($1.35)||($0.77)||$1.85 million||$2.54 million||View||Listen|
|12/5/2016||Q416||($1.48)||($0.89)||$2.85 million||$2.16 million||View||Listen|
|2/10/2016||Q116||($1.53)||($0.10)||$4.61 million||$5.40 million||View||Listen|
|12/7/2015||Q415||($1.38)||($0.85)||$15.00 million||$5.60 million||View||N/A|
|8/6/2015||Q315||($1.30)||($1.60)||$12.82 million||$13.55 million||View||N/A|
|5/11/2015||Q215||($1.23)||($0.58)||$11.38 million||$9.43 million||View||Listen|
|2/4/2015||Q115||($0.91)||($0.26)||$12.12 million||$12.40 million||View||N/A|
|12/2/2014||Q414||($0.46)||$0.02||$9.15 million||$12.03 million||View||N/A|
|8/6/2014||Q314||($0.62)||($0.66)||$12.88 million||$13.00 million||View||N/A|
|5/7/2014||Q114||($0.30)||$0.49||$12.48 million||$12.55 million||View||N/A|
|2/4/2014||Q413||($0.34)||($0.02)||$11.54 million||$7.49 million||View||N/A|
|8/5/2013||Q313||($0.11)||$0.02||$10.71 million||$11.04 million||View||N/A|
Earnings Estimates for GW Pharmaceuticals PLC (NASDAQ:GWPH)
2017 EPS Consensus Estimate: ($8.16)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for GW Pharmaceuticals PLC (NASDAQ:GWPH)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for GW Pharmaceuticals PLC (NASDAQ GWPH)
No insider trades for this company have been tracked by MarketBeat.com
Latest Headlines for GW Pharmaceuticals PLC (NASDAQ GWPH)
|GW Pharmaceuticals to Present at Upcoming Investor Conferences - Nasdaq|
www.nasdaq.com - November 23 at 1:11 AM
|GW Pharmaceuticals: Bull Thesis Strengthened And Further Upside Expected - Seeking Alpha|
seekingalpha.com - November 23 at 1:11 AM
|Today’s Research Reports on Stocks to Watch: Sage Therapeutics and GW Pharmaceuticals|
finance.yahoo.com - November 22 at 8:09 PM
|Enjoy the Holiday Trading While It Lasts|
finance.yahoo.com - November 21 at 7:22 PM
|GW Pharmaceuticals PLC (GWPH) Stock Rating Reaffirmed by Cantor Fitzgerald|
www.americanbankingnews.com - November 20 at 11:34 PM
|Bank of America Corporation Lowers GW Pharmaceuticals PLC (GWPH) Price Target to $158.00|
www.americanbankingnews.com - November 15 at 12:58 AM
|7 Marijuana Stocks to Buy That Won't Burn You | InvestorPlace - Investorplace.com|
investorplace.com - November 11 at 5:16 AM
|Successful Cannabis Legalization Campaigns Influence Market|
www.prnewswire.com - November 9 at 6:25 AM
|$2.61 Million in Sales Expected for GW Pharmaceuticals PLC (GWPH) This Quarter|
www.americanbankingnews.com - November 8 at 5:46 AM
| Brokerages Expect GW Pharmaceuticals PLC (GWPH) to Announce -$1.82 Earnings Per Share|
www.americanbankingnews.com - November 6 at 5:24 PM
|GW Pharmaceuticals PLC (GWPH) Receives Average Rating of "Buy" from Analysts|
www.americanbankingnews.com - November 6 at 1:40 AM
|GW Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish for GWPH - Nasdaq|
www.nasdaq.com - November 5 at 2:08 AM
|Politics Is The Main Uncertainty For GW Pharma - Seeking Alpha|
seekingalpha.com - November 3 at 5:39 AM
|GW Pharma (GWPH) Completes Rolling NDA Submission to FDA for ... - StreetInsider.com|
www.streetinsider.com - October 30 at 8:14 PM
|GW Pharmaceuticals and its U.S. Subsidiary Greenwich Biosciences Completes Rolling New Drug Application Submission to U.S. Food and Drug Administration for Epidiolex® (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome and Dravet Syndrome|
finance.yahoo.com - October 30 at 8:14 PM
|ETFs with exposure to GW Pharmaceuticals Plc : October 27, 2017|
finance.yahoo.com - October 28 at 6:20 AM
|Head to Head Review: GW Pharmaceuticals PLC- (GWPH) vs. Radius Health (RDUS)|
www.americanbankingnews.com - October 27 at 7:24 PM
|The 5-Minute Guide on How to Invest in Marijuana Stocks|
finance.yahoo.com - October 22 at 6:03 PM
|Why Marijuana Stocks Won't Pay a Dividend, Even if They're Profitable|
finance.yahoo.com - October 20 at 8:59 PM
|4 Medical Product Stocks Likely to Top Q3 Earnings Estimates - Nasdaq|
www.nasdaq.com - October 19 at 1:28 AM
|4 Medical Product Stocks Likely to Top Q3 Earnings Estimates|
finance.yahoo.com - October 19 at 1:28 AM
| Analysts Expect GW Pharmaceuticals PLC (GWPH) to Post -$1.39 EPS|
www.americanbankingnews.com - October 18 at 12:12 AM
|Future Legal Cannabis Sales Projected to Rise - PR Newswire (press release)|
www.prnewswire.com - October 16 at 9:01 PM
|GW Pharmaceuticals PLC (GWPH) Receives Consensus Rating of "Buy" from Analysts|
www.americanbankingnews.com - October 12 at 12:48 AM
|GW Pharmaceuticals PLC (GWPH) Receives Neutral Rating from Goldman Sachs Group, Inc. (The)|
www.americanbankingnews.com - October 6 at 8:34 PM
|This Potential Billion-Dollar Marijuana-Based Drug Suddenly Finds Itself in Deep Trouble|
finance.yahoo.com - October 6 at 8:47 AM
|Zogenix - Share Offering And Double Top Reversal|
seekingalpha.com - October 4 at 1:46 PM
|What Do Zogenix Drug Study Results Mean For GW Pharmaceuticals' Epidiolex? - Benzinga|
www.benzinga.com - October 3 at 9:20 AM
|How Risky Is GW Pharmaceuticals Stock After Zogenix's Big News?|
finance.yahoo.com - October 3 at 9:19 AM
|Zogenix Stock Nears 7-Year High On Excitement Over Epilepsy Drug|
finance.yahoo.com - October 2 at 6:50 PM
|GW Pharmaceuticals PLC (GWPH) Rating Reiterated by Cowen and Company|
www.americanbankingnews.com - October 2 at 1:56 PM
|December 15th Options Now Available For GW Pharmaceuticals (GWPH)|
www.nasdaq.com - October 2 at 1:49 PM
|ETFs with exposure to GW Pharmaceuticals Plc : October 2, 2017|
finance.yahoo.com - October 2 at 1:49 PM
|GW Pharmaceuticals PLC (GWPH) Price Target Cut to $153.00 by Analysts at Leerink Swann|
www.americanbankingnews.com - October 2 at 10:16 AM
|Pre-Open Movers 09/29: (ZGNX) (VERI) (ROKU) Higher; (GWPH) (PRTA) (GLYC) Lower (more...)|
www.streetinsider.com - September 29 at 4:39 PM
|Zogenix Soars After Epilepsy Drug Meets Primary Endpoint -Biotech Movers|
www.thestreet.com - September 29 at 10:55 AM
|GW Pharmaceuticals (GWPH) Shares Cross Above 200 DMA|
www.nasdaq.com - September 28 at 8:24 PM
|Medical Cannabis Companies Leverage Biosynthesis to Boost Drug Development|
www.prnewswire.com - September 26 at 11:21 AM
|Can You Guess What Sears, GameStop, Spirit Airlines, Tootsie Roll, and Papa John's All Have in Common?|
finance.yahoo.com - September 22 at 1:11 PM
|ETFs with exposure to GW Pharmaceuticals Plc : September 22, 2017|
finance.yahoo.com - September 22 at 1:11 PM
|GW Pharmaceuticals PLC (GWPH) Given Average Recommendation of "Buy" by Brokerages|
www.americanbankingnews.com - September 17 at 12:52 AM
|Montel Williams' Battle With Multiple Sclerosis And The Miracle Of Medical Marijuana|
finance.yahoo.com - September 15 at 8:00 PM
|Investors' Biggest Worry About GW Pharmaceuticals Could Be the Biotech's Ace in the Hole|
finance.yahoo.com - September 14 at 8:01 PM
| Brokerages Anticipate GW Pharmaceuticals PLC (GWPH) Will Announce Quarterly Sales of $2.61 Million|
www.americanbankingnews.com - September 12 at 3:56 PM
|ETFs with exposure to GW Pharmaceuticals Plc : September 12, 2017|
finance.yahoo.com - September 12 at 1:27 AM
|Corporate News Blog - Leadership Change in Novartis as CEO Jimenez to Retire in 2018; Vasant Narasimhan Named His Successor|
finance.yahoo.com - September 6 at 7:18 PM
|GW Pharmaceuticals to Present at Upcoming Investor Conferences ... - GlobeNewswire (press release)|
globenewswire.com - September 6 at 4:04 AM
|GW Pharmaceuticals to Present at Upcoming Investor Conferences|
finance.yahoo.com - September 6 at 4:04 AM
|GW Pharmaceuticals PLC (GWPH) & Paratek Pharmaceuticals (PRTK) Head-To-Head Survey|
www.americanbankingnews.com - September 2 at 10:28 AM
|ETFs with exposure to GW Pharmaceuticals Plc : August 31, 2017|
finance.yahoo.com - August 31 at 7:13 PM
Financials are not available for this stock.
GW Pharmaceuticals PLC (NASDAQ GWPH) Chart for Saturday, November, 25, 2017